Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

04-03-2021 | Semaglutide | Commentary | Article

STEP 2: A higher semaglutide dose in people with type 2 diabetes

print
PRINT
insite
SEARCH

Ildiko Lingvay discusses the STEP 2 findings, and why a higher semaglutide dose may be optimal for most people with type 2 diabetes (8:06).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Keep up with the latest results from the STEP trials

Read the quick guide


About the speaker

Ildiko Lingvay

Ildiko Lingvay is Professor in the Division of Endocrinology and the Department of Population and Data Sciences at the University of Texas (UT) Southwestern Medical Center in Dallas, TX, USA.


Full biography

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content

11-03-2020 | Liraglutide (obesity) | Highlight | News

Liraglutide 3.0 mg boosts weight loss in insulin-dependent type 2 diabetes

11-02-2021 | Semaglutide | At a glance | Article

A quick guide to the STEP trials

11-02-2021 | Semaglutide | News

STEP 1: Semaglutide promotes substantial weight loss in people without diabetes

24-02-2021 | Semaglutide | News

STEP 3: Semaglutide boosts weight loss during intensive behavioral therapy
Image Credits